CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation

Trac, Noah; Chen, Leng-Ying; Zhang, Ailin; Liao, Chun-Peng; Poon, Christopher; Wang, Jonathan; Ando, Yuta; Joo, Johan; Garri, Carolina; Shen, K. Robert; Kani, Kian; Gross, Mitchell E.; Chung, Eun Ji

doi:10.1016/j.jconrel.2020.09.054

Cited by 27 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of CCR2 (activated by its ligands) in the induction of migration and invasion in tumor cells including melanomas has been reported in recent studies [ 37 , 38 ]. The therapeutic block of the CCL2/CCR2 axis has yielded promising results to slow the progression of several tumor types [ 39 , 40 , 41 ]; the therapy of melanoma-targeting CCR2 inhibited tumor growth in laboratory animals [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines

Koroknai

Szász

Jámbor

et al. 2022

IJMS

View full text Add to dashboard Cite

Cytokine and chemokine receptors can promote tumor progression, invasion, and metastasis development by inducing different intracellular signaling pathways. The aim of this study was to determine the cytokine and chemokine receptor gene expression patterns in human melanoma cell lines. We found a large set of cytokine and chemokine receptor genes that were significantly differentially expressed between melanoma cell lines that originated from different subtypes of primary melanomas as well as cell lines that originated from melanoma metastases. The relative expressions of two receptor genes (CCR2 and TNFRSF11B) were positively correlated with the invasive potential of the cell lines, whereas a negative correlation was observed for the TNFRSF14 gene expression. We also found a small set of receptor genes that exhibited a significantly decreased expression in association with a BRAFV600E mutation. Based on our results, we assume that the analyzed cytokine and chemokine receptor collection may provide potential to distinguish the different subtypes of melanomas, helping us to understand the biological behavior of BRAFV600E-mutated melanoma cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines

Koroknai

Szász

Jámbor

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Jung et al engineered 7C1 nanoparticles loaded with CX3CL1 on 7C1, which successfully reduced the expression of CX3CL1 and prevented the recruitment of macrophages toward the tumor region [ 130 ]. Recently, KLAK-MCP-1 micelles containing a CCR2-targeting peptide sequence and apoptotic KLAK peptide to induce apoptosis were synthesized to interrupt the MCP-1/CCR2 axis, which successfully inhibited tumor growth in B16F10 melanoma by inhibiting the infiltration of TAMs into the tumor and elevating cytotoxic T lymphocytes [ 128 ]. In another recent study, the researcher engineered CCR2-targeting ultrasmall copper nanoparticles (Cu@CuO x ) as a nanovehicle loaded with gemcitabine for PET-guided drug delivery into pancreatic ductal adenocarcinoma tumors.…”

Section: Main Textmentioning

confidence: 99%

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Kumari

Choi

2022

J Exp Clin Cancer Res

133

View full text Add to dashboard Cite

Cancer immunotherapy has emerged as a novel cancer treatment, although recent immunotherapy trials have produced suboptimal outcomes, with durable responses seen only in a small number of patients. The tumor microenvironment (TME) has been shown to be responsible for tumor immune escape and therapy failure. The vital component of the TME is tumor-associated macrophages (TAMs), which are usually associated with poor prognosis and drug resistance, including immunotherapies, and have emerged as promising targets for cancer immunotherapy. Recently, nanoparticles, because of their unique physicochemical characteristics, have emerged as crucial translational moieties in tackling tumor-promoting TAMs that amplify immune responses and sensitize tumors to immunotherapies in a safe and effective manner. In this review, we mainly described the current potential nanomaterial-based therapeutic strategies that target TAMs, including restricting TAMs survival, inhibiting TAMs recruitment to tumors and functionally repolarizing tumor-supportive TAMs to antitumor type. The current understanding of the origin and polarization of TAMs, their crucial role in cancer progression and prognostic significance was also discussed in this review. We also highlighted the recent evolution of chimeric antigen receptor (CAR)-macrophage cell therapy.

show abstract

“…To inhibit CCL2 and its cognate receptor CCR2 axis, Shen et al synthesized siCCR2-encapsulated cationic nanoparticle (CNP/siCCR2) to inhibit primary tumor progression and further metastasis by reducing the abundance of TAMs and altering the immunosuppressive tumor microenvironment ( Shen et al, 2018 ). In another recent study, Trac et al designed KLAK-MCP-1 micelles, consisting of a CCR2-targeting peptide sequence and apoptotic KLAK peptide, which were effective in inhibiting tumor growth by blocking infiltration of TAMs in a subcutaneous B16F10 murine melanoma model ( Trac et al, 2021 ). Zhang et al loaded gemcitabine onto ultrasmall copper nanoparticles (Cu@CuO x) for PET-guided drug delivery, which could specifically target CCR2 and synergize the therapeutic effects of gemcitabine, ultimately slowing the growth of pancreatic ductal carcinoma ( Zhang X. et al, 2021 ).…”

Section: Np-based Delivery Systems For Cancer Immunotherapymentioning

confidence: 99%

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Liu

Huang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is a major cause of incidence rate and mortality worldwide. In recent years, cancer immunotherapy has made great progress in the preclinical and clinical treatment of advanced malignant tumors. However, cancer patients will have transient cancer suppression reaction and serious immune related adverse reactions when receiving immunotherapy. In recent years, nanoparticle-based immunotherapy, which can accurately deliver immunogens, activate antigen presenting cells (APCs) and effector cells, provides a new insight to solve the above problems. In this review, we discuss the research progress of nanomaterials in immunotherapy including nanoparticle-based delivery systems, nanoparticle-based photothermal and photodynamic immunotherapy, nanovaccines, nanoparticle-based T cell cancer immunotherapy and nanoparticle-based bacteria cancer immunotherapy. We also put forward the current challenges and prospects of immunomodulatory therapy.

show abstract

CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation

Cited by 27 publications

References 50 publications

Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines

Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Contact Info

Product

Resources

About